Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study
| Autor: | Lian Li, Bo Wang, Limin Zheng, Shengping Li, Yuan Liao, Zhi Liang Huang, Ming Shi, Xing Juan Yu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Male Pathology medicine.medical_treatment Cancer Treatment Prospective Studies Stage (cooking) Prospective cohort study Immune Response Multidisciplinary T Cells Liver Neoplasms Natural killer T cell Treatment Outcome Hepatocellular carcinoma Medicine Female Adjuvant Research Article Adult medicine.medical_specialty Carcinoma Hepatocellular Science Immune Cells Immunology Immunomodulation Immune system Diagnostic Medicine Internal medicine Gastrointestinal Tumors medicine Humans Chemoembolization Therapeutic Biology Aged business.industry Therapeutic effect Cancers and Neoplasms Hepatocellular Carcinoma Chemotherapy and Drug Treatment medicine.disease Th17 Cells Clinical Immunology business CD8 Biomarkers General Pathology |
| Zdroj: | PLoS ONE PLoS ONE, Vol 8, Iss 4, p e60444 (2013) |
| ISSN: | 1932-6203 |
| Popis: | Transarterial chemoembolization (TACE) has therapeutic effects in patients with unresectable hepatocellular carcinoma (HCC), but its impact on the cellular immune response during disease progression is largely unknown. Here we conducted a prospective study to evaluate the effect of TACE on immune status and to identify prognostic immune markers governing treatment success. In this study, 51 stage III HCC patients, 28 stage I HCC patients (TNM classification) and 20 healthy donors were enrolled. Flow cytometry and cytometric bead array were used to evaluate the circulating immune cell subsets, including CD4(+) T cells (Th1, Th17 and Treg cells), CD8(+) T cells, NK cells, and NKT cells, and plasma cytokines before TACE and 30 days after TACE. Interestingly, among those immune parameters, the frequency of circulating Th17 cells was higher in stage III HCC patients than in stage I HCC patients (P = 0.015) and healthy donors (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|